EMERGENT BIOSOLUTIONS INC (EBS)
US29089Q1058 - Common Stock
Taking everything into account, EBS scores 1 out of 10 in our fundamental rating. EBS was compared to 588 industry peers in the Biotechnology industry. EBS has a bad profitability rating. Also its financial health evaluation is rather negative. EBS does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
EBS had negative earnings in the past year.
EBS had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: EBS reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: EBS reported negative operating cash flow in multiple years.
1.2 Ratios
With a Return On Assets value of -51.75%, EBS perfoms like the industry average, outperforming 48.21% of the companies in the same industry.
The Return On Equity of EBS (-145.31%) is worse than 65.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -51.75% | ||
| ROE | -145.31% | ||
| ROIC | N/A |
ROA(3y)-13.66%
ROA(5y)-5.61%
ROE(3y)-39.61%
ROE(5y)-18.54%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of EBS (29.14%) is better than 76.58% of its industry peers.
EBS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for EBS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.14% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.37%
GM growth 5Y-11.03%
2. Health
2.1 Basic Checks
EBS does not have a ROIC to compare to the WACC, probably because it is not profitable.
EBS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for EBS has been increased compared to 5 years ago.
EBS has a worse debt/assets ratio than last year.
2.2 Solvency
EBS has an Altman-Z score of 0.09. This is a bad value and indicates that EBS is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.09, EBS is in the better half of the industry, outperforming 62.22% of the companies in the same industry.
A Debt/Equity ratio of 0.69 indicates that EBS is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.69, EBS is doing worse than 75.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.69 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.09 |
ROIC/WACCN/A
WACC5.13%
2.3 Liquidity
EBS has a Current Ratio of 1.04. This is a normal value and indicates that EBS is financially healthy and should not expect problems in meeting its short term obligations.
EBS has a Current ratio of 1.04. This is amonst the worse of the industry: EBS underperforms 88.03% of its industry peers.
A Quick Ratio of 0.54 indicates that EBS may have some problems paying its short term obligations.
EBS has a worse Quick ratio (0.54) than 95.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.04 | ||
| Quick Ratio | 0.54 |
3. Growth
3.1 Past
The earnings per share for EBS have decreased strongly by -142.48% in the last year.
EBS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.34%.
Measured over the past years, EBS shows a small growth in Revenue. The Revenue has been growing by 6.05% on average per year.
EPS 1Y (TTM)-142.48%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-148.39%
Revenue 1Y (TTM)8.34%
Revenue growth 3Y-12.3%
Revenue growth 5Y6.05%
Revenue growth Q2Q-16.36%
3.2 Future
Based on estimates for the next years, EBS will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.79% on average per year.
EBS is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -6.04% yearly.
EPS Next Y63.14%
EPS Next 2Y63.6%
EPS Next 3Y25.8%
EPS Next 5Y14.79%
Revenue Next Year-3.99%
Revenue Next 2Y2.7%
Revenue Next 3Y-8.59%
Revenue Next 5Y-6.04%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
EBS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EBS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
EBS's earnings are expected to grow with 25.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y63.6%
EPS Next 3Y25.8%
5. Dividend
5.1 Amount
No dividends for EBS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EMERGENT BIOSOLUTIONS INC
NYSE:EBS (4/17/2024, 7:04:00 PM)
After market: 1.92 +0.02 (+1.05%)1.9
-0.05 (-2.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap99.18M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -51.75% | ||
| ROE | -145.31% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.14% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.69 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.04 | ||
| Quick Ratio | 0.54 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-142.48%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y63.14%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)8.34%
Revenue growth 3Y-12.3%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y